GlassScriptPhysician profile
Vivek V Sailam
NPI 1386819589
$28,431.67
in general payments reported to CMS, 2019-2025
37 companies · $1,526 in 2025
The $1,526 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $11K · 2021: $1,312 · 2022: $799 · 2023: $712 · 2024: $1,294 · 2025: $1,526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,531.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $19,634.60 | 2019-2024 | Xarelto |
| Amgen INC. | $1,604.66 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $1,205.56 | 2019-2025 | |
| Boston Scientific Corporation | $748.00 | 2019-2025 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $534.81 | 2019-2025 | Jardiance |
| Pfizer INC. | $534.68 | 2019-2025 | |
| Impulse Dynamics (USA) INC. | $500.26 | 2019-2025 | Optimizer, Optimizer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $498.30 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $468.73 | 2019-2022 | |
| Esperion Therapeutics, INC. | $385.29 | 2020-2025 | Nexletol |
| Abbott Laboratories | $262.57 | 2020-2025 | Aveir, Navitor |
| Astrazeneca Pharmaceuticals LP | $226.89 | 2019-2025 | Farxiga |
| Actelion Pharmaceuticals US, INC. | $181.26 | 2024-2025 | Uptravi, Opsumit |
| Amarin Pharma, INC. | $166.03 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $164.96 | 2019-2023 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivek Sailam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.